Diabetes Discourse

Guest: Robert Cuddihy, MD Host: Steven Edelman, MD There have been impressive results with incretin-based therapy for patients with type 2 diabetes: improved A1C, beta-cell preservation and weight loss are some of the benefits. But do healthcare professionals need to temper their enthusiasm for this novel therapy? Join host Dr. Steven Edelman and his guest, medical director of the International Diabetes Center, Park Nicollet Health Services, Dr. Robert Cuddihy, as they discuss whether incretin-based therapy holds promise of a truly disease-modifying therapy.